VRCI Stock Overview
An immuno-diagnostics development company, focuses on the kidney transplantation market.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Verici Dx plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.08 |
52 Week High | UK£0.15 |
52 Week Low | UK£0.055 |
Beta | 1.53 |
1 Month Change | 0% |
3 Month Change | -21.95% |
1 Year Change | -36.00% |
3 Year Change | -88.89% |
5 Year Change | n/a |
Change since IPO | -78.08% |
Recent News & Updates
Shareholder Returns
VRCI | GB Biotechs | GB Market | |
---|---|---|---|
7D | -4.2% | -0.1% | -0.6% |
1Y | -36.0% | -21.0% | 7.7% |
Return vs Industry: VRCI underperformed the UK Biotechs industry which returned -20.7% over the past year.
Return vs Market: VRCI underperformed the UK Market which returned 6.5% over the past year.
Price Volatility
VRCI volatility | |
---|---|
VRCI Average Weekly Movement | 6.7% |
Biotechs Industry Average Movement | 8.2% |
Market Average Movement | 4.9% |
10% most volatile stocks in GB Market | 11.1% |
10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: VRCI's share price has been volatile over the past 3 months.
Volatility Over Time: VRCI's weekly volatility has decreased from 14% to 7% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2020 | 14 | Sara Barrington | www.vericidx.com |
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its lead products comprise Tutivia, a post-transplant test focused on acute rejection, including sub-clinical rejection; and Clarava, a pre-transplant prognosis test for the risk of early acute rejection.
Verici Dx plc Fundamentals Summary
VRCI fundamental statistics | |
---|---|
Market cap | UK£19.40m |
Earnings (TTM) | -UK£8.82m |
Revenue (TTM) | UK£14.94k |
1,299x
P/S Ratio-2.2x
P/E RatioIs VRCI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
VRCI income statement (TTM) | |
---|---|
Revenue | US$19.00k |
Cost of Revenue | US$3.00k |
Gross Profit | US$16.00k |
Other Expenses | US$11.23m |
Earnings | -US$11.21m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.046 |
Gross Margin | 84.21% |
Net Profit Margin | -59,015.79% |
Debt/Equity Ratio | 0% |
How did VRCI perform over the long term?
See historical performance and comparison